AU2001245298A1 - Use of pentosan polysulfate for the manufacture of a medicament for the treatment of male chronic pelvic pain syndrome - Google Patents

Use of pentosan polysulfate for the manufacture of a medicament for the treatment of male chronic pelvic pain syndrome

Info

Publication number
AU2001245298A1
AU2001245298A1 AU2001245298A AU4529801A AU2001245298A1 AU 2001245298 A1 AU2001245298 A1 AU 2001245298A1 AU 2001245298 A AU2001245298 A AU 2001245298A AU 4529801 A AU4529801 A AU 4529801A AU 2001245298 A1 AU2001245298 A1 AU 2001245298A1
Authority
AU
Australia
Prior art keywords
medicament
manufacture
treatment
pain syndrome
pelvic pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001245298A
Inventor
Stephen L. Cartt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of AU2001245298A1 publication Critical patent/AU2001245298A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001245298A 2000-02-25 2001-02-20 Use of pentosan polysulfate for the manufacture of a medicament for the treatment of male chronic pelvic pain syndrome Abandoned AU2001245298A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18518500P 2000-02-25 2000-02-25
US60/185,185 2000-02-25
US60185185 2000-02-25
PCT/US2001/005364 WO2001062263A2 (en) 2000-02-25 2001-02-20 Use of pentosan polysulfate for the manufacture of a medicament for the treatment of male chronic pelvic pain syndrome

Publications (1)

Publication Number Publication Date
AU2001245298A1 true AU2001245298A1 (en) 2001-09-03

Family

ID=22679949

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001245298A Abandoned AU2001245298A1 (en) 2000-02-25 2001-02-20 Use of pentosan polysulfate for the manufacture of a medicament for the treatment of male chronic pelvic pain syndrome

Country Status (3)

Country Link
US (1) US20010034328A1 (en)
AU (1) AU2001245298A1 (en)
WO (1) WO2001062263A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005216651A1 (en) * 2004-03-01 2005-09-09 Bioxell Spa Treatment of interstitial cystitis with vitamin D compounds
US20100041630A1 (en) * 2007-02-14 2010-02-18 Prelief Inc. Methods for Treating or Preventing Inflammation Using a Glycerophosphate Salt
CN103764824B (en) 2011-06-20 2018-04-24 西奈山医学院 The anti-tnf-alpha therapy of mucopolysaccharidosis and other lysosome illnesss
EP3842048A4 (en) 2018-08-20 2022-03-30 ReqMed Company, Ltd. Novel pentosan polysulfate sodium preparation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3842362A1 (en) * 1988-12-16 1990-06-28 Hoechst Ag PHARMACEUTICAL COMBINATION PREPARATIONS CONTAINING NUCLEOSIDE DERIVATIVES AND PENTOSANPOLYSULFATE, AND THEIR PREPARATION AND USE

Also Published As

Publication number Publication date
US20010034328A1 (en) 2001-10-25
WO2001062263A3 (en) 2002-07-18
WO2001062263A2 (en) 2001-08-30

Similar Documents

Publication Publication Date Title
MXPA03009971A (en) Pharmaceutical dosage form of amorphous nelfinavir mesylate.
IL196301A0 (en) Medicament for the treatment of hapatitis c
WO2001078698A3 (en) Use of ngf-antagonists for the prevention or treatment of chronic visceral pain
HK1062408A1 (en) Remedies for infant chronic arthritis-relating diseases
WO2007081949A3 (en) Small-volume oral transmucosal dosage forms
AU2002246152A1 (en) Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases
HUP0301815A3 (en) Mono and disaccharide-based pharmaceutical composition for infections and other diseases and prophylactic and therapeutic treatment
AU2180400A (en) A pharmaceutical combination for the treatment of depression
AU2002344924A1 (en) Administration appliance comprising a dosage device
PT1441705E (en) Solid, stabilized, prompt- and/or modified-release therapeutical systems for the oral administration of liquid active principles, excipients or foodstuffs
MXPA03005731A (en) Absorbent article having releasable medicinal treatments.
AU1724301A (en) Hydrogel-driven layered drug dosage form
HK1096854A1 (en) Use of a pak inhibitor for the manufacturing a medicament for the treatment of a joint disease pak
AU2001279595A1 (en) Bandage for treatment of pressure sores, bedsores and similar ailments
AU2002357830A1 (en) Methods and devices for therapeutic treatment cardiac and other pathologies
ZA200203156B (en) Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrindependent microcirculation disorders.
GB2368525B (en) Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
AU2002226427A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
AU2001243515A1 (en) Combination drug therapy
AU2001245298A1 (en) Use of pentosan polysulfate for the manufacture of a medicament for the treatment of male chronic pelvic pain syndrome
IL155431A0 (en) Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders
AU2002252610A1 (en) Ultrasonic profiling of medicament administration into tissue
AU2003209542A1 (en) Use of s-substituted l-crysteine for the manufacture of a medicament for the treatment of dermatological disorders
AU2002311141A1 (en) The use of hydrochloric acid in the preparation of a medicament for the treatment of tumour
AU3071999A (en) Use of pkc inhibitors for the manufacture of a medicament for the treatment of autoimmune diseases